專欄新型冠狀病毒

Any Covid-19 vaccine must be treated as a global public good

Imagine if, in a year’s time, 300m doses of a safe and effective Covid-19 vaccine have been manufactured in Donald Trump’s America, Xi Jinping’s China or Boris Johnson’s Britain. Who is going to get them? What are the chances that a nurse in India, or a doctor in Brazil, let alone a bus driver in Nigeria or a diabetic in Tanzania, will be given priority? The answer must be virtually nil.

The ugly battle between nations over limited supplies of tests and personal protective equipment will be a sideshow compared to the scramble over a vaccine. Yet if a vaccine is to be anything like the silver bullet that some imagine, it will have to be available to the world’s poor as well as to its rich. 

Any vaccine should be deployed to create the maximum possible benefit to public health. That will mean prioritising doctors, nurses and other frontline workers, as well as those most vulnerable to the disease, no matter where they live or how much they can afford.

您已閱讀20%(961字),剩餘80%(3792字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。

戴維•皮林

戴維•皮林(David Pilling)現爲《金融時報》非洲事務主編。先前他是FT亞洲版主編。他的專欄涉及到商業、投資、政治和經濟方面的話題。皮林1990年加入FT。他曾經在倫敦、智利、阿根廷工作過。在成爲亞洲版主編之前,他擔任FT東京分社社長。

相關文章

相關話題

設置字型大小×
最小
較小
默認
較大
最大
分享×